CDK4 and neoplasm: The combination of fulvestrant, palbociclib and capiversertib (an inhibitor of AKT1, AKT2 and AKT3) has been shown to be effective in suppressing tumor growth in preclinical models that were dually resistant to ET and CDK4/6 inhibitors (Alves et al., 2021).